Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2024 - 2025)

Prelude Therapeutics' Total Non-Current Liabilities history spans 2 years, with the latest figure at $69.8 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 70.48% year-over-year to $69.8 million; the TTM value through Dec 2025 reached $69.8 million, up 70.48%, while the annual FY2025 figure was $69.8 million, 70.48% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $69.8 million at Prelude Therapeutics, up from $33.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $69.8 million in Q4 2025 and bottomed at $33.1 million in Q1 2024.